New Antibody-Drug conjugate 3H-10000 enters human trials for Hard-to-Treat cancers

NCT ID NCT07354711

Recruiting now Disease control Sponsor: 3H Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called 3H-10000, which is an antibody-drug conjugate designed to target and kill cancer cells. It is for people with advanced lung or stomach cancer that cannot be removed by surgery or has spread. The trial will enroll 170 participants to find the safest dose and see if the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 3H-10000 (an antibody-drug conjugate targeting FGFR2b)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced lung or stomach cancer that has not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with only 170 participants, so the drug may not prove effective or safe enough for wider use. Side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm lung cancer lung neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER STOMACH CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.